Cancer immunotherapy has been a game-changer, but many tumors still find ways to slip past the immune system. New research ...

Leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells Remarkably longer survival was observed in patients treated with ...

Cancer immunotherapy has transformed modern oncology by harnessing the body's own immune system to combat malignant disease.

The FDA accepted a supplemental biologics license application and granted priority review for Datroway for adults ...

PD-L1 expression predicts better outcomes with nivolumab and ipilimumab in ccRCC, aligning with previous trial results. High KIM-1 expression is linked to worse DFS, suggesting its potential as a ...

A total of 871 patient samples were retrospectively tested using the VENTANA PD-L1 (SP263) assay (Roche Diagnostics, Indianapolis, IN), including 481 enrolled patients and 390 patients who did not ...

The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology to include ...

Kazia stated that in murine triple-negative breast cancer preclinical models, NDL2 reduced primary tumor volume by 49% as ...

FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients FDA priority ...